• Duarte Rego Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar Universitário do Porto
  • Gabriela Teixeira Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar Universitário do Porto
  • Daniel Mendes Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar Universitário do Porto
  • Paulo Almeida Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar Universitário do Porto
  • Rui Almeida Serviço de Angiologia e Cirurgia Vascular, Centro Hospitalar Universitário do Porto



Deep Vein Thrombosis, Thrombolytic therapy, Catheter-directed thrombolysis, Post-thrombotic syndrome, Cancer, Pregnancy


Introduction: Post-thrombotic syndrome is associated with severely decreased quality of life and develops in up to 50% of patients with iliofemoral deep vein thrombosis (DVT) despite effective anticoagulation. Catheter-directed thrombolysis (CDT) use has become widespread and is supported by a growing body of scientific evidence (including randomized controlled trials). However, almost all of these trials have excluded two groups of patients in which DVT has a particularly increased burden: pregnant women and patients with active cancer.

Aims: This non-systematic review of literature aims to provide a comprehensive analysis of the existing evidence on the safety and efficacy of CDT for iliofemoral DVT in these subgroups of patients.

Results: Endovascular treatment of iliofemoral DVT during pregnancy and puerperium seems safe and effective both for the pregnant woman and the fetus. The risks of radiation (especially in the first trimester) must be discussed and taken in consideration.

CDT and pharmacomechanical thrombolysis (PMT) are both safe and effective in patients with active cancer, as long as metastatic brain lesions are excluded. However, effective anticoagulation (with low-molecular weight heparin or, in selected patients, direct oral anticoagulants) should be prescribed after the intervention to maintain patency in these patients with continued thrombophilia. 

Conclusions: CDT, with or without PMT, should be offered to pregnant patients and patients with active cancer provided that a careful risk-benefit assessment is made for each individual patient.


Download data is not yet available.


1. Kahn SR, Shbaklo H, Lamping DL, et al. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. J Thromb Haemost. 2008, 6, pp. 1105-12.
2. Delis KT, Bountouroglou D, Mansfield AO. Venous claudication in iliofemoral thrombosis: long-term effects on venous hemodynamics, clinical status, and quality of life. Ann Surg. 2004, 239, pp. 118-26.
3. Kahn, SR. The post-thrombotic syndrome. Hematology Am Soc Hematol Educ Program. 2010, pp. 216–220.
4. Kahn SR, Shrier I, Julian JA, et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med. 2008, Vol. 149, pp. 698-707.
5. Haller JA, Abrams BL. Use of thrombectomy in the treatment of acute iliofemoral venous thrombosis in forty-five patients. Ann Surg. 1963, Vol. 158 (4), pp. 561–6.
6. Lansing AM, Davis WM. Five-year follow-up study of iliofemoral venous thrombectomy. Ann Surg. 1968, Vol. 168(4), pp. 620–8.
7. Plate G, Einarsson E, Eklof B, et al. Iliac vein obstruction associated with acute iliofemoral venous thrombosis. Results of early reconstruction using polytetrafluoroethylene grafts. Acta Chir Scand. 1985, Vol. 151, 7, pp. 607–11.
8. Common HH, Seaman AJ, Rosch J, Porter JM, Dotter CT. Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study. Angiology. 1976, Vol. 27, pp. 645–54.
9. lliot MS, Immelman EJ, Jeffrey P, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg. 1979, Vol. 66, pp. 838–43.
10. Arneson H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective study. Acta Med Scand. 1992, Vol. 211, pp. 65– 8.
11. Goldhaber SZ, Meyerovitz MF, Green D, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med. 1990, Vol. 88, pp. 235-40.
12. Turpie AG, Levine MN, Hirsh J, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. Chest. 1990, Vol. 97, pp. 172s-5s.
13. Watson L, Broderick C, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev. 2014, Vol. 1, CD002783.
14. Albers GW, Bates VE, Clark WM, et al. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000, Vol. 283, pp. 1145-50.
15. Schweizer J, Kirch W, Koch R, et al. Short- and Long-Term Results After Thrombolytic Treatment of Deep Venous Thrombosis. J Am Coll Cardiol. 2000, Vol. 36, 4, pp. 1336-43.
16. Oklu R, Wicky S. Catheter-directed thrombolysis of deep venous thrombosis. Semin Thromb Hemost. 2013, Vol. 39, pp. 446-51.
17. Vedantham S, Sista AK, Klein SJ, et al. Quality improvement guidelines for the treatment of lower-extremity deep vein thrombosis with use of endovascular thrombus removal. J Vasc Interv Radiol. 2014, Vol. 25, pp. 1317-25.
18. Elbasty A, Metcalf J. Safety and Efficacy of Catheter Direct Thrombolysis in Management of Acute Iliofemoral Deep Vein Thrombosis: A Systematic Review. Vasc Specialist Int. 2017, Vol. 33, pp. 121–134.
19. Wang L, Zhang C, Mu S, et al. Safety of catheter-directed thrombolysis for the treatment of acute lower extremity deep vein thrombosis: A systematic review and meta-analysis. Medicine. 2017, Vol. 96, 35, p. e7922.
20. Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg. 2002, Vol. 24, pp. 209-14.
21. Enden T, Haig Y, Kløw NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet. 2012, Vol. 379, pp. 31–38.
22. Haig Y, Enden T, Grøtta O, et al. Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. Lancet Haematol. 2016, Vol. 3, 2, pp. e64 - e71.
23. Haig Y, Enden T, Slagsvold CE, et al. Determinants of early and long-term efficacy of catheter-directed thrombolysis in proximal deep vein thrombosis. J Vasc Interv Radiol. 2013, Vol. 24, 1, pp. 17-24.
24. Vedantham S, Goldhaber SZ, Julian JA, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Deep-Vein Thrombosis. N Engl J Med. 2017, Vol. 377, 23, pp. 2240-2252.
25. Sharifi M, Bay C, Mehdipour M, Sharifi J. Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion (TORPEDO) trial: midterm results. J Endovasc Ther. 2012, Vol. 19, 2, pp. 273-80.
26. Meissner MH, Gloviczki P, Comerota AJ, et al. Early thrombus removal strategies for acute deep venous thrombosis: Clinical Practice Guidelines of the Society for Vascular Surgery and the American Venous Forum. J Vasc Surg. 2012, Vol. 55, 5, pp. 1449-62.
27. DUTCH CAVA-trial: CAtheter Versus Anticoagulation Alone for Acute Primary (Ilio)Femoral DVT. 2009.
28. Lin M, Hsieh JCF, Hanif M, et al. Evaluation of thrombolysis using tissue plasminogen activator in lower extremity deep venous thrombosis with concomitant femoral-popliteal venous segment involvement. J Vasc Surg Venous Lymphat Disord. 2017, Vol. 5, 5, pp. 613-620.
29. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005, Vol. 143, pp. 697-706.
30. Pomp ER, Lenselink AM, Rosendaal FR, et al. The postpartum period and prothrombotic defects:risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008, Vol. 6, pp. 632-7.
31. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999, Vol. 94, 1, pp. 730-4.
32. B, Brenner. Haemostatic changes in pregnancy. Thromb Res. 2004, Vol. 114, pp. 409-14.
33. James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors and mortality. Am J Obstet Gynecol. 2006, Vol. 194, p. 1311.
34. Tassi R, Acampa M, Marotta G, et al. Systemic thrombolysis for stroke in pregnancy. Am J Emerg Med. 2013, Vol. 31, 448, pp. 1-3.
35. The 2007 Recommendations of the International Commission on Radiological Protection. Ann ICRP. 2007, Vol. 37, pp. 1-332.
36. Tirada N, Dreizin D, Khati NJ, et al. Imaging Pregnant and Lactating Patients. Radiographics. 2015, Vol. 35, pp. 1751-65.
37. BA, Atwell TD, et al. Radiation Exposure and Pregnancy: When Should We Be Concerned? Radiographics. 2007, Vol. 27, pp. 909-17.
38. Siah TH, Chapman A. Should catheter-directed thrombolysis be the standard of care for pregnancy-related iliofemoral deep vein thrombosis? BMJ Case Reports. 2018.
39. Kearon C, Julian JA, Math M, et al. Noninvasive diagnosis of deep venous thrombosis. McMaster diagnostic imaging practice guidelines initiative. Ann Intern Med. 1998, Vol. 128, pp. 663-77.
40. Messina LM, Sarpa MS, Smith MA, et al. Clinical significance of routine imaging of iliac and calf veins by color flow duplex scanning in patients suspected of having acute lower extremity deep venous thrombosis. Surgery. 1993, Vol. 114, pp. 921-7.
41. Tversky S, Libman RB, Reppucci ML, et al. Thrombolysis for Ischemic Stroke during Pregnancy: A Case Report and Review of the Literature. J Stroke Cerebrovasc Dis. 2016, Vol. 25, 10, pp. 167-70.
42. Leffert LR, Clancy CR, Bateman BT, et al. Treatment patterns and short-term outcomes in ischemic stroke in pregnancy or postpartum period. Am J Obstet Gynecol. 2016, Vol. 214, 723, pp. 1-11.
43. Bloom AI, Farkas A,Kalish Y, et al. Pharmacomechanical Catheter-Directed Thrombolysis for Pregnancy-Related Iliofemoral Deep Vein Thrombosis. J Vasc Interv Radiol. 2015, Vol. 26, 7, pp. 992-1000.
44. Herrera S, Comerota AJ, Thakur S, et al. Managing iliofemoral deep venous thrombosis of pregnancy with a strategy of thrombus removal is safe and avoids post-thrombotic morbidity. J Vasc Surg. 2014, Vol. 59, 2, pp. 456-64.
45. Hartung O, Barthelemy P, Arnoux D, et al. Management of pregnancy in women with previous left ilio-caval stenting. J Vasc Surg. 2009, Vol. 50, pp. 355-9.
46. Dasari M, Avgerinos E, Raju S, et al. Outcomes of iliac vein stents after pregnancy. J Vasc Surg Venous Lymphat Disord. 2017, Vol. 5, 3, pp. 353-357.
47. Heit JA, Silverstein MD, Mohr DN, etal. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000, Vol. 160, 6, pp. 809–815.
48. SR, Deitcher. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Hemost. 2003, Vol. 29, pp. 247-58.
49. Hutten BA, Prins MH, Gent M, et al. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000, Vol. 18, pp. 3078-83.
50. Prandoni P, Lensing AWA, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002, Vol. 100, pp. 3484-8.
51. Mikkola KM, Patel SR, Parker JA, et al. Attenuation over 24 hours of the efficacy of thrombolysis of pulmonary embolism among patients with cancer. Am Heart J. 1997, Vol. 134, pp. 603-7.
52. Cappellari M, Carletti M, Micheletti N, et al. Intravenous Alteplase for acute ischemic stroke in patients with current malignant neoplasm. J Neurol Sci. 2013, Vol. 325, pp. 100-2.
53. Masrur S, Abdullah AR, Smith EE, et al. Risk of thrombolytic therapy for acute ischemic stroke in patients with current malignancy. J Stroke Cerebrovasc Dis. 2011, Vol. 20, 2, pp. 124-30.
54. Kim HS, Preece SR, Black JH, et al. Safety of catheter-directed thrombolysis for deep venous thrombosis in cancer patients. J Vasc Surg. 2008, Vol. 47, 2, pp. 388-94.
55. Administration, U.S. Food and Drug. [Online]
56. O'Sullivan GJ, Lohan DG, Gough N, Cronin CG, Kee ST. Pharmacomechanical thrombectomy of acute deep vein thrombosis with the Trellis-8 isolated thrombolysis catheter. J Vasc Interv Radiol. 2007, Vol. 18, 6, pp. 715-24.
57. Yoon WJ, Halandras P, Aulivola B, Crisostomo P. Malignancy Does not Affect Outcomes of Pharmacomechanical Thrombolysis in Acute Symptomatic Iliofemoral Deep Vein Thrombosis. Ann Vasc Surg. 2018.
58. Avgerinos ED, Hager ES, Naddaf A, Dillavou E, Singh M, Chaer RA. Outcomes and predictors of failure of thrombolysis for iliofemoral deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2015, Vol. 3, 1, pp. 35-41.
59. Farge D, Bounameaux H, Brenner B, et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016, Vol. 17, 10, pp. e452-e466.
60. Makam RCP, Hoaglin DC, McManus DD, et al. Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis. PLoS One. 2018, Vol. 13, e0197583.
61. Young AM, Marshall A, Thirlwall J, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018, Vol. 10.
62. Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018, Vol. 378, 7, pp. 615-624.
63. AYY, Lee. Overview of VTE treatment in cancer according to clinical guidelines. Thromb Res. 2018, Vol. 164, pp. S162-S167.
64. Wysokinska EM, Sobande F, Wysokinski WE, Bjarnason H, McBane Ii RD. Iliac vein thrombosis: feasibility assessment of randomized controlled trials of endovascular pharmacomechanical thrombolysis. J Thromb Haemost. 2010, Vol. 8, 9, pp. 1943-9.
65. Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients:a meta-analysis. JAMA. 2008, Vol. 300, pp. 2277–85.
66. Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996, Vol. 14, pp. 2731–7.
67. Debourdeau P, Farge D, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost. 2013, Vol. 11, 1, pp. 71-80.
68. Khorana AA, ConnollyGC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol. 2009, Vol. 27, pp. 4839–47.
69. Kyriazi V, Theodoulou E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch Pathol Lab Med. 2013, Vol. 137, pp. 1286–95




How to Cite

Rego D, Teixeira G, Mendes D, Almeida P, Almeida R. CATHETER-DIRECTED THROMBOLYSIS FOR DEEP VENOUS THROMBOSIS IN PREGNANT WOMEN AND PATIENTS WITH ACTIVE CANCER (A COMPREHENSIVE REVIEW). Angiol Cir Vasc [Internet]. 2019 May 15 [cited 2024 Jun. 21];14(4):339-46. Available from:



Review Article